Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4123524 A
Publication typeGrant
Application numberUS 05/804,601
Publication dateOct 31, 1978
Filing dateJun 8, 1977
Priority dateJun 8, 1977
Publication number05804601, 804601, US 4123524 A, US 4123524A, US-A-4123524, US4123524 A, US4123524A
InventorsLeroy B. Townsend, Arthur F. Lewis, Linda W. Roti Roti
Original AssigneeThe United States Of America As Represented By The Department Of Health, Education And Welfare
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia
US 4123524 A
Abstract
The compound 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazines-5'-phosphate (a nucleotide) as a new compound and its method of synthesis by phosphorylation of the known 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine (a nucleoside). The 5'-phosphate ester has utility against L-1210 mouse leukemia and has superior solubility over the parent compound which gives it a broader use pattern relative to dosage. This novel nucleotide also shows advantage in utilization as to pH over, for example, the hydrochloride salt which gives in solution a pH of 4 and is too acid for use.
Images(3)
Previous page
Next page
Claims(2)
We claim:
1. The compound 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine-5'-phosphate.
2. The method of alleviating and treating L-1210 mouse leukemia which comprises injecting intraperitoneally over a 9-day administration span daily an anti-leukemic dosage of the compound 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine-5'-phosphate in a dose range of 8-62 mg/kg.
Description

The synthesis of the 5'-phosphate or 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido-[4,5-c]pyridazine-5'-phosphate, a nucleotide, from the parent nucleoside compound [Schram and Townsend, Tetrahedron Letters, 49:4757-4760 (1971)] is set out below in Formula I: ##STR1##

6-Amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine-5'-phosphate (II, NSC #280594) was synthesized by a direct phosphorylation of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine (I, NSC #154020) by a modification of the procedure of Yoshikawa, et al, Tetrahedron Letters, 50:5065 (1967) and using the isolation procedure described for adenosine monophosphate by Imai et al, J. Org. Chem., 34:1547 (1969).

The method utilized the phosphoryl chloride in excess (3-5 molar excess) at 0-10 C. for 2-4 hours. Trialkyl phosphate was used as an accelerator for the phosphorylation and facilitates the phosphorylation with phosphoryl chloride (or phosphorous oxychloride). Anhydrous trialkyl phosphates, such as trimethyl and triethyl phosphates, are preferred and advantage is taken of the solubility of the nucleoside in the trialkyl phosphate. Typical yields run 20-30%.

PRIOR ART

U.s. pat. No. 3,502,649 Thiel et al.

U.s. pat. No. 3,590,029 Koch et al.

U.s. pat. No. 3,819,613 Marumoto et al.

U.s. pat. No. 3,936,439 Marumoto et al.

None of the above patented compounds show the novel tricyclic structure of the present compound.

The phosphate ester compound shown above as II has shown activity in a broad range of dosages against L-1210 mouse leukemia.

It has been found that the cytotoxicity for L-1210 in vitro is similar for the 5'-monophosphate (II) and NSC 154020 (I), with ID50 's of 2.5 10-8 M and 3.5 10-8 M respectively.

The 5'-monophosphate (II) shows anti-L-1210 in vivo comparable to NSC 154020, but over a broader range of dosages and without the host toxicity associated with treatment with NSC 154020.

The modus of treatment is intraperitioneal and the dosage to the host mice is approximately 8-62 mg/kg per diem. A typical course involved daily treatment for 9 days.

The protocol utilized was Protocol 11 of the National Cancer Institute published in Cancer Chemotherapy Reports of September 1972, Volume 3, No. 2, Part 2.

Application of the anticancer tricyclic nucleoside (I above) has been hindered by formulation (insolubility) problems. The present water-soluble 5'-phosphate ester of this nucleoside has apparently solved the insolubility problem.

EXAMPLE 1

The nucleoside (I, 1.6 g, 4.7 mmoles) was dissolved in 30 ml of dry, redistilled trimethyl phosphate. The solution was stirred and cooled to 0 2 C. A mixture of 2 ml (3.35 g, 21.9 mmole) of phosphorous oxychloride and 5 ml of trimethyl phosphate was added slowly (approx. 30 min) maintaining a reaction temperature of 0 2 C. The reaction was stirred in the cold (0 2 C.) for 30 min. more and then refrigerated (0 2 C.) for 16 hr. The reaction was poured onto 100 ml of crushed ice and the resulting solution stirred for approx. 15 min. The pH was adjusted to 2 by the addition of cold 4 N sodium hydroxide. The solution was extracted with chloroform (3 100 ml) and then stirred with 40 g of activated charcoal. The charcoal was first washed with water (1 l) and then ethanol--conc. ammonium hydroxide--water (25:1:24 v/v/v) approx. 1.5 l) to elute the reaction products. The alcoholic-ammonia solution was evaporated in vacuo to a volume of approx. 50 ml, and this solution then applied to a column of Dowex 1 8 (HCOO-) (25 ml). The Dowex was washed with water until no detectable u.v. absorbing material was eluting (750 ml). The Dowex was then washed with 0.05 N formic acid (500 ml) and then with 0.1 N formic acid (2 l), collecting 20 ml fractions. The fractions containing the major product (35-95) were combined and the solution evaporated in vacuo to a volume of 100 ml. Ethanol (100 ml) was added and the mixture refrigerated for several hours. The solid was collected by filtration, washed with ethanol (20 ml) and dried in vacuo. Yield = 390 mg (0.913 mmole, 21%). The solid was recrystallized from water (65% recovery) and dried in vacuo to give a pure compound. Anal. calc'd for C13 H17 N6 O7 P . 1.5 H2 O: C, 36.54; H, 4.72; N, 19.67; O, 31.83. Found: C, 36.54; H, 4.72; N, 19.88; O, 31.07. U.v. λmax (nm), ε 10-3 : pH 1, 315 (5.66), 287 (11.4), 280.5 (11.4); pH 11, 320 sh (7.37), 292 (12.6); methanol, 322 sh (7.37), 293 (12.8). U.v. λmin, ε 10- 3 : pH 1, 258 (5.13), pH 11, 256 (3.11); methanol, 257.5 (2.88).

A 34% yield of the 5'-phosphate (II) was obtained when anhydrous I (4 mmole) was allowed to react with 3 equivalents (12 mmoles) of phosphorous oxychloride which had been prereacted with 1 equivalent (4 mmoles) of water.

EXAMPLE 2

______________________________________Activity of Tricyclic Nucleoside (NSC #154020)and the 5'-Monophosphate (NSC #280594) Against L-1210 invivo as Indicated in Survival Times of L-1210 BearingMiceT/C = Mean Lifespan of Treated Animals/Mean Lifespan ofControl AnimalsMolar Equivalent  T/C (%)Dose (in water)/Injection)   Nucleotide(mg/kg administered intro-   (5'Phosphateperitoneally on Days 1-9)             Nucleoside Derivative)NSC       NSC         NSC        NSC#154020   #280594     #154020    #280594______________________________________50        62.5        (toxic)    14337.5      46.9        (toxic)    17425        31.25       (toxic)    15918.75     23.45       135        15312.5      15.63       148        1259.4       11.73       126        1326.25      7.81        129        132______________________________________

As above noted and in extensive additional testing, Compound I, the nucleoside (NSC #154020), has shown consistently good activity against mouse leukemia L-1210 in vivo, in the approximate dose range 6-19 mg/kg, with T/C's ranging up to 215, with two cures (animals surviving 30 days). Host toxicity prevented the use of higher doses. In contrast, the nucleotide (5'-phosphate derivative) NSC #280594 has shown excellent activity with no host toxicity up to 62.5 mg/kg, the highest dose tested.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3413282 *Mar 29, 1966Nov 26, 1968Ajinomoto KkMethod of preparing 5'-nucleotides
Non-Patent Citations
Reference
1 *Towsend, L. and Schram, K., Tetrahedron Letter, 1971, No. 49, pp. 4757-4760.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5633235 *Jul 5, 1994May 27, 1997Regents Of The University Of MichiganTriciribine and analogs as antiviral drugs
US5827833 *Dec 19, 1996Oct 27, 1998Regents Of The University Of MichiganTriciribine and analogs as antiviral drugs
US6413944Dec 20, 1999Jul 2, 2002Regents Of The University Of MichiganTriciribine and analogs as antiviral drugs
US6600028 *Apr 2, 1998Jul 29, 2003Amersham Pharmacia Biotech Uk LimitedTricyclic base analogues
US8435959Mar 29, 2005May 7, 2013University Of South FloridaEffective treatment of tumors and cancer with triciribine and related compounds
US8623834Apr 23, 2012Jan 7, 2014University Of South FloridaCompositions including triciribine and trastuzumab and methods of use thereof
US8673867Apr 23, 2012Mar 18, 2014University Of South FloridaCompositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US8673868Apr 23, 2012Mar 18, 2014University Of South FloridaCompositions including triciribine and one or more platinum compounds and methods of use thereof
US8691779Apr 20, 2012Apr 8, 2014University Of South FloridaCompositions including triciribine and taxanes and methods of use thereof
US8865666Apr 23, 2012Oct 21, 2014University Of South FloridaCompositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US8901086May 3, 2012Dec 2, 2014University Of South FloridaCompositions including triciribine and methods of use thereof
EP1694642A2 *Dec 10, 2004Aug 30, 2006Koronis Pharmaceuticals, Inc.Mutagenic heterocycles
EP1737472A2 *Mar 29, 2005Jan 3, 2007University Of South FloridaEffective treatment of tumors and cancer with triciribine and related compounds
EP2574341A1Mar 29, 2005Apr 3, 2013University Of South FloridaEffective treatment of tumors and cancer with triciribine and related compounds
WO2003061385A1 *Oct 1, 2002Jul 31, 2003An HaoyunTricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2008121261A2 *Mar 25, 2008Oct 9, 2008Vioquest Pharmaceuticals IncProdrugs of triciribin suitable for treatment of tumors and cancer
WO2015009897A1 *Jul 17, 2014Jan 22, 2015Rythrx Therapeutics, LlcCompositions and methods for preserving red blood cells and platelets
Classifications
U.S. Classification514/52, 536/26.1, 514/908, 536/27.1
International ClassificationC07H19/14
Cooperative ClassificationY10S514/908, C07H19/14
European ClassificationC07H19/14